{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:14:10Z","timestamp":1788880450353,"version":"build-2803163510"},"reference-count":80,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018694","name":"European Commission Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","award":["101120256"],"award-info":[{"award-number":["101120256"]}],"id":[{"id":"10.13039\/100018694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omtn.2026.103062","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:15:05Z","timestamp":1786634105000},"page":"103062","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and toxicity assessment of antisense oligonucleotides in brain-relevant human cellular models"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2506-8498","authenticated-orcid":false,"given":"Laura","family":"Colar Zanjko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"Andr\u00e9s-Santamaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Balogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willeke M.C.","family":"van Roon-Mom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3791-2583","authenticated-orcid":false,"given":"Andr\u00e1s","family":"Dinny\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.103062_bib1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s43856-023-00419-1","article-title":"Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders","volume":"4","author":"Lauffer","year":"2024","journal-title":"Commun. Med."},{"key":"10.1016\/j.omtn.2026.103062_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/nat.2017.0665","article-title":"FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2026.103062_bib3","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40265-023-01904-6","article-title":"Tofersen: First Approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.omtn.2026.103062_bib4","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease","volume":"381","author":"Kim","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.103062_bib5","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/s41586-023-06277-0","article-title":"A framework for individualized splice-switching oligonucleotide therapy","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103062_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf346","article-title":"The N=1 Collaborative: advancing customized nucleic acid therapies through collaboration and data sharing","volume":"53","author":"Belgrad","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.103062_bib7","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.75.1.285","article-title":"Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide","volume":"75","author":"Stephenson","year":"1978","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.103062_bib8","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.103062_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27020536","article-title":"Small Drugs, Huge Impact: The Extraordinary Impact of Antisense Oligonucleotides in Research and Drug Development","volume":"27","author":"Quemener","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.omtn.2026.103062_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232113359","article-title":"Recent Progress and Challenges in the Development of Antisense Therapies for Myotonic Dystrophy Type 1","volume":"23","author":"De Serres-B\u00e9rard","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2026.103062_bib11","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/nar\/gkaf1333","article-title":"Acute neuronal inhibition response caused by phosphorothioate antisense oligonucleotides following local delivery to the central nervous system","volume":"54","author":"O'Rourke","year":"2026","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.103062_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102692","article-title":"Unraveling and controlling late-onset neurotoxicity of antisense oligonucleotides through strategic chemical modifications","volume":"36","author":"Kuroda","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103062_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkag484","article-title":"Enhanced splicing modulation by NMA-modified antisense oligonucleotides","volume":"54","author":"Ling","year":"2026","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.103062_bib14","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.129240","article-title":"Brain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging","volume":"4","author":"Mazur","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtn.2026.103062_bib15","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/nar\/gkaa1235","article-title":"The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration","volume":"49","author":"Jafar-Nejad","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.103062_bib16","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1124\/jpet.113.212407","article-title":"Pharmacology of a central nervous system delivered 2'-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates","volume":"350","author":"Rigo","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.omtn.2026.103062_bib17","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2026.103062_bib18","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.drudis.2018.05.030","article-title":"Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development","volume":"23","author":"Andersson","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.omtn.2026.103062_bib19","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1089\/nat.2018.0772","article-title":"Guidelines for Experiments Using Antisense Oligonucleotides and Double-Stranded RNAs","volume":"29","author":"Gagnon","year":"2019","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2026.103062_bib20","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/mds.28359","article-title":"Hydrocephalus Complicating Intrathecal Antisense Oligonucleotide Therapy for Huntington's Disease","volume":"36","author":"Stoker","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.omtn.2026.103062_bib21","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3233\/JND-230032","article-title":"Symptomatic intracranial hypertension in an adult patient with spinal muscular atrophy and arachnoid cysts receiving nusinersen","volume":"10","author":"Machetanz","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.omtn.2026.103062_bib22","doi-asserted-by":"crossref","first-page":"34501","DOI":"10.1039\/D0RA04978F","article-title":"In vivo and in vitro studies of antisense oligonucleotides - a review","volume":"10","author":"Kilanowska","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.omtn.2026.103062_bib23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41573-024-01059-3","article-title":"The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap","volume":"24","author":"Jonker","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2026.103062_bib24","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1261\/rna.079540.122","article-title":"Development of tailored splice-switching oligonucleotides for progressive brain disorders in Europe: development, regulation, and implementation considerations","volume":"29","author":"Aartsma-Rus","year":"2023","journal-title":"RNA"},{"key":"10.1016\/j.omtn.2026.103062_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102615","article-title":"Tailored antisense oligonucleotides for ultrarare CNS diseases: An experience-based best practice framework for individual patient evaluation","volume":"36","author":"Sch\u00fcle","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103062_bib32","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/s41467-025-67752-y","article-title":"Antisense oligonucleotides to KIF1A polymorphisms expand targets and rescue patient-derived neurons in vitro","volume":"17","author":"Zuccaro","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103062_bib33","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41586-024-07310-6","article-title":"Antisense oligonucleotide therapeutic approach for Timothy syndrome","volume":"628","author":"Chen","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103062_bib34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.omtn.2022.06.015","article-title":"Developing antisense oligonucleotides for a TECPR2 mutation-induced, ultra-rare neurological disorder using patient-derived cellular models","volume":"29","author":"Williams","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103062_bib35","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1038\/s41591-024-03197-y","article-title":"Antisense oligonucleotide therapy in an individual with KIF1A-associated neurological disorder","volume":"30","author":"Ziegler","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.103062_bib36","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s12964-025-02304-x","article-title":"Modeling neuroinflammatory interactions between microglia and astrocytes in a human iPSC-based coculture platform","volume":"23","author":"Tujula","year":"2025","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.omtn.2026.103062_bib37","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/MS9.0000000000002760","article-title":"Brain tumors and induced pluripotent stem cell technology: a systematic review of the literature","volume":"87","author":"Shayestehfar","year":"2025","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.omtn.2026.103062_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.941528","article-title":"Cerebral Organoids and Antisense Oligonucleotide Therapeutics: Challenges and Opportunities","volume":"15","author":"Lange","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.omtn.2026.103062_bib39","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41586-024-08462-1","article-title":"Rapid and scalable personalized ASO screening in patient-derived organoids","volume":"638","author":"Means","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103062_bib40","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1177\/21593337251361396","article-title":"Characterizing Antibodies Targeting Antisense Oligonucleotide Phosphorothioate and 2'-O-Methoxyethyl Modifications for Intracellular Trafficking and Biodistribution Studies","volume":"35","author":"Fial","year":"2025","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2026.103062_bib41","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.omtn.2023.05.005","article-title":"Lipid nanoparticle delivery limits antisense oligonucleotide activity and cellular distribution in the brain after intracerebroventricular injection","volume":"32","author":"Byrnes","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103062_bib42","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nbt.3779","article-title":"Cellular uptake and trafficking of antisense oligonucleotides","volume":"35","author":"Crooke","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.103062_bib43","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/nar\/gkz1132","article-title":"Hybridization-mediated off-target effects of splice-switching antisense oligonucleotides","volume":"48","author":"Scharner","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.103062_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12091933","article-title":"Calcium-Enhanced Medium-Based Delivery of Splice Modulating Antisense Oligonucleotides in 2D and 3D hiPSC-Derived Neuronal Models","volume":"12","author":"Buijsen","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.omtn.2026.103062_bib45","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1261\/rna.071290.119","article-title":"Efficient electroporation of neuronal cells using synthetic oligonucleotides: identifying duplex RNA and antisense oligonucleotide activators of human frataxin expression","volume":"25","author":"Shen","year":"2019","journal-title":"RNA"},{"key":"10.1016\/j.omtn.2026.103062_bib46","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1042\/BCJ20170632","article-title":"Lipid-based DNA\/siRNA transfection agents disrupt neuronal bioenergetics and mitophagy","volume":"474","author":"Napoli","year":"2017","journal-title":"Biochem. J."},{"key":"10.1016\/j.omtn.2026.103062_bib47","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1089\/nat.2021.0021","article-title":"Oligonucleotides Targeting DNA Repeats Downregulate Huntingtin Gene Expression in Huntington's Patient-Derived Neural Model System","volume":"31","author":"Umek","year":"2021","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2026.103062_bib48","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3389\/fncel.2018.00313","article-title":"Effective Knockdown of Gene Expression in Primary Microglia With siRNA and Magnetic Nanoparticles Without Cell Death or Inflammation","volume":"12","author":"Carrillo-Jimenez","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.omtn.2026.103062_bib49","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13024-024-00725-9","article-title":"Regulation of human microglial gene expression and function via RNAase-H active antisense oligonucleotides in vivo in Alzheimer's disease","volume":"19","author":"Vandermeulen","year":"2024","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.omtn.2026.103062_bib50","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.celrep.2018.07.106","article-title":"Nuclear Localization of Huntingtin mRNA Is Specific to Cells of Neuronal Origin","volume":"24","author":"Didiot","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2026.103062_bib51","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1021\/bc00010a001","article-title":"Development of sensitive radioiodinated anti-sense oligonucleotide probes by conjugation technique","volume":"2","author":"Dewanjee","year":"1991","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.omtn.2026.103062_bib52","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1089\/nat.2023.0018","article-title":"Biodistribution of Radioactively Labeled Splice Modulating Antisense Oligonucleotides After Intracerebroventricular and Intrathecal Injection in Mice","volume":"34","author":"Metz","year":"2024","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2026.103062_bib53","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.cgt.7700787","article-title":"Antitumor effects of radioiodinated antisense oligonuclide mediated by VIP receptor","volume":"12","author":"Ou","year":"2005","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omtn.2026.103062_bib54","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.2174\/1381612023394467","article-title":"Labelled oligonucleotides as radiopharmaceuticals: pitfalls, problems and perspectives","volume":"8","author":"Younes","year":"2002","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.omtn.2026.103062_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/nar\/gkaa1112","article-title":"High-resolution visualization and quantification of nucleic acid-based therapeutics in cells and tissues using Nanoscale secondary ion mass spectrometry (NanoSIMS)","volume":"49","author":"He","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.103062_bib56","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0168-0102(02)00014-7","article-title":"Delivery of antisense oligonucleotides to PC12 cells","volume":"43","author":"Acosta","year":"2002","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.omtn.2026.103062_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90629-1","article-title":"Fluorescent base analogues in gapmers enable stealth labeling of antisense oligonucleotide therapeutics","volume":"11","author":"Nilsson","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2026.103062_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173401","article-title":"Monitoring integrity and localization of modified single-stranded RNA oligonucleotides using ultrasensitive fluorescence methods","volume":"12","author":"Heissig","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2026.103062_bib59","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/nar\/gky1158","article-title":"Quantitative fluorescence imaging determines the absolute number of locked nucleic acid oligonucleotides needed for suppression of target gene expression","volume":"47","author":"Buntz","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.103062_bib60","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/s41467-021-21021-w","article-title":"Short antisense oligonucleotides alleviate the pleiotropic toxicity of RNA harboring expanded CGG repeats","volume":"12","author":"Derbis","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103062_bib61","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0026-895X(25)09229-6","article-title":"Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides","volume":"41","author":"Bennett","year":"1992","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.omtn.2026.103062_bib62","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.omtn.2017.06.017","article-title":"Antisense Oligonucleotides Reduce RNA Foci in Spinocerebellar Ataxia 36 Patient iPSCs","volume":"8","author":"Matsuzono","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103062_bib63","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jmoldx.2011.08.002","article-title":"RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues","volume":"14","author":"Wang","year":"2012","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.omtn.2026.103062_bib64","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1089\/nat.2024.0065","article-title":"Bioanalytical Assays for Oligonucleotide Therapeutics: Adding Antibody-Based Immunoassays to the Toolbox as an Orthogonal Approach to LC-MS\/MS and Ligand Binding Assays","volume":"35","author":"Chimento","year":"2025","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2026.103062_bib65","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1093\/hmg\/ddaf153","article-title":"Determining off-target effects of splice-switching antisense oligonucleotides using short read RNAseq in neuronally differentiated human induced pluripotent stem cells","volume":"34","author":"Kuijper","year":"2025","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2026.103062_bib66","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.omtn.2021.11.015","article-title":"Allele-specific targeting of mutant ataxin-3 by antisense oligonucleotides in SCA3-iPSC-derived neurons","volume":"27","author":"Hauser","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103062_bib67","first-page":"3467","article-title":"NLRP3-directed antisense oligonucleotides reduce microglial immunoactivities in vitro","volume":"168","author":"Braatz","year":"2024","journal-title":"J. Neurochem."},{"key":"10.1016\/j.omtn.2026.103062_bib68","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/nat.2021.0071","article-title":"Acute Neurotoxicity of Antisense Oligonucleotides After Intracerebroventricular Injection Into Mouse Brain Can Be Predicted from Sequence Features","volume":"32","author":"Hagedorn","year":"2022","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2026.103062_bib69","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.omtn.2022.12.010","article-title":"Change of intracellular calcium level causes acute neurotoxicity by antisense oligonucleotides via CSF route","volume":"31","author":"Jia","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103062_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102359","article-title":"Preventing acute neurotoxicity of CNS therapeutic oligonucleotides with the addition of Ca2+ and Mg2+ in the formulation","volume":"35","author":"Miller","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103062_bib71","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/nbt.2376","article-title":"Assessing unintended hybridization-induced biological effects of oligonucleotides","volume":"30","author":"Lindow","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.103062_bib72","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/embo-reports\/kvd001","article-title":"The G x U wobble base pair. A fundamental building block of RNA structure crucial to RNA function in diverse biological systems","volume":"1","author":"Varani","year":"2000","journal-title":"EMBO Rep."},{"key":"10.1016\/j.omtn.2026.103062_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102186","article-title":"ASOptimizer: Optimizing antisense oligonucleotides through deep learning for IDO1 gene regulation","volume":"35","author":"Hwang","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.103062_bib74","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/gtc.12587","article-title":"Estimated number of off-target candidate sites for antisense oligonucleotides in human mRNA sequences","volume":"23","author":"Yoshida","year":"2018","journal-title":"Genes Cells"},{"key":"10.1016\/j.omtn.2026.103062_bib75","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.3390\/genes16121468","article-title":"Artificial Intelligence-Driven Design of Antisense Oligonucleotides for Precision Medicine in Neuromuscular Disorders","volume":"16","author":"Leckie","year":"2025","journal-title":"Genes"},{"key":"10.1016\/j.omtn.2026.103062_bib76","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1016\/j.csbj.2025.09.022","article-title":"ASOG: AntiSense Oligonucleotide Generator","volume":"27","author":"Kimi","year":"2025","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.omtn.2026.103062_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2023.1130925","article-title":"A mechanistic pharmacokinetic model for intrathecal administration of antisense oligonucleotides","volume":"14","author":"Linninger","year":"2023","journal-title":"Front. Physiol."},{"key":"10.1016\/j.omtn.2026.103062_bib78","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1016\/j.jtha.2024.08.003","article-title":"CpG oligonucleotides induce acute murine thrombocytopenia dependent on toll-like receptor 9 and spleen tyrosine kinase pathways","volume":"22","author":"Johansson","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.omtn.2026.103062_bib79","article-title":"Integrating transcriptomics and proteomics to assess antisense oligonucleotide safety and efficacy: a time-resolved approach","volume":"3","author":"van Leeuwen","year":"2026","journal-title":"NAR Mol. Med."},{"key":"10.1016\/j.omtn.2026.103062_bib80","doi-asserted-by":"crossref","first-page":"8107","DOI":"10.1093\/nar\/gkac618","article-title":"Insights into innate immune activation via PS-ASO-protein-TLR9 interactions","volume":"50","author":"Pollak","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2026.103062_bib81","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0313514","article-title":"Efficient derivation of functional astrocytes from human induced pluripotent stem cells (hiPSCs)","volume":"19","author":"Szeky","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2026.103062_bib82","doi-asserted-by":"crossref","first-page":"17931","DOI":"10.1021\/acs.jmedchem.4c02052","article-title":"Dose\u2013Response Curves and the Determination of IC50 and EC50 Values Bharath Srinivasan","volume":"67","author":"Srinivasan","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.omtn.2026.103062_bib83","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/s41591-026-04314-9","article-title":"Antisense oligonucleotide-mediated knockdown therapy in two infants with severe KCNT1 epileptic encephalopathy","volume":"32","author":"Nakayama","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.103062_bib84","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1002\/mds.29201","article-title":"Targeted Molecular Therapeutics for Parkinson's Disease: A Role for Antisense Oligonucleotides?","volume":"37","author":"Li","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.omtn.2026.103062_bib85","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/CND.0000000000000517","article-title":"Tofersen for Amyotrophic Lateral Sclerosis: Genetic Treatment With Precision Medicine: The Future of ALS Treatment","volume":"26","author":"Hamad","year":"2025","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"10.1016\/j.omtn.2026.103062_bib86","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s10072-025-07994-2","article-title":"Tofersen for SOD1 amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"46","author":"Hamad","year":"2025","journal-title":"Neurol. Sci."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126002337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126002337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:04:02Z","timestamp":1788879842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253126002337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2162253126002337"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103062","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and toxicity assessment of antisense oligonucleotides in brain-relevant human cellular models","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"103062"}}